NCT03110588 - Phase I Trial of PACE for Metastatic Prostate Cancer | Biotech Hunter

Timeline

Start Date

May 9, 2018

Primary Completion Date

December 18, 2019

Study Completion Date

December 18, 2019

Conditions

Metastatic Prostate Cancer

Interventions

DRUG

PACE with Cabazitaxel (15 mg/m2)

Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 15 mg/m2.

DRUG

PACE with Cabazitaxel (20 mg/m2)

Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 20 mg/m2.

Trial Locations (1)

University of Alabama at Birmingham, Birmingham